SLAS SBS OrlandoConference Prelim Program

Gaylord Palms Resort and Convention Center
March 27–31, 2011 | Orlando, Florida, USA

SLAS.org/events/sbs11
Preliminary Program
Register by January 24
for Maximum Savings!
Table of Contents
Welcome Page 3
Schedule-at-a-Glance Page 4
What’s New and Exciting for SBS 2011 Page 6
Short Course Program Overview Page 7
Keynote Speakers Page 10
Technical Session Program Overview Page 11
Special Educational Sessions Page 15
SLAS Career Connections Page 15
Special Interest Groups (SIGs) Page 16
Exhibition Page 17
General Information Page 19
Social Events and Networking Page 20
Registration Form Page 21
SBS 2011 Scientific Committee, SLAS Board of Directors,

BSS Executive Council, LAS Executive Council Page 23
Sponsors and Media Partners Back Cover
2 | SLAS.org/events/sbs11
Dear Colleagues,
On behalf of the Society for Laboratory Automation and Screening (SLAS), we invite
you to join us at the 17th Annual SBS Conference and Exhibition in Orlando, Florida.
We are proud to host this exciting event, which includes:
• Engaging keynote presentations by SBS Achievement Award winner

Robert J. Lefkowitz, SBS Accomplishment Award winner Brian Shoichet,
and Professor Hugh Rosen of The Scripps Research Institute
• An outstanding scientific program and thought-provoking poster presentations
• An exhibit floor thriving with leading companies from around the world
• Informative vendor tutorials and collaborative Special Interest Groups (SIGs)
• Innovative new programs and awards
Most importantly, SBS 2011 provides a place for you to come together with other
scientists, engineers and professionals involved in the science of drug discovery
and screening to learn, and share ideas, research and innovation.
As a conference participant, you may choose from 15 diverse scientific sessions

organized in three tracks, with each session punctuated by a keynote presentation:
Track I: Innovations in the Screening Sciences

This track captures the excitement of recent advances in all aspects of the screening
sciences, with a focus on innovations in instrumentation, reagents and technologies
that are impacting “HTS to Lead” efforts.
Track II: Translational Research

These sessions describe the changing face of drug discovery in the 21st century and
introduce collaborative paradigms and resources that enhance translational research.
Track III: Sequenced Genomes: Reducing Opportunities to Practice

This track explores how the availability of sequenced genomes and the inevitability
of inexpensive phenotyping are impacting therapeutic agent and consumer product
discovery. And most importantly, these sessions illustrate how screening sciences
are ideally positioned to take advantage of these opportunities.
Collectively, the range of offerings this year enables participants to remain at the
forefront of emerging capabilities in this field. SBS 2011 is an event you won’t want
to miss—we look forward to seeing you in Orlando!
Paul Bernasconi and Peter Hodder

SBS 2011 Program Chairs
SLAS.org/events/sbs11 |3
Schedule-at-a-Glance* | New and Improved Hours!
* Schedule Subject to Change
Sunday, March 27

8:30 am – 5:00 pm Short Courses
»» Automated Assays for Drug Discovery: A Toolbox Approach to Selecting an
Appropriate Assay
»» BacMam101: Practical Aspects of Making and Using BacMam Vectors
»» Establishing Cell-Based Assays for Screening
»» In Vitro ADME Screening: Basic Concepts and Practical Methods
»» Label-Free/Biophysics Methods for Screening
»» Statistical Methods for In Vitro Assays in Drug Discovery
»» High-Content Screening
9:00 am – 12:00 pm Exhibitor Workshops

1:00 – 4:00 pm BioAssay Ontology: Development of an Industry Standard for the Description
and Categorization of Small Molecule High-Throughput Screening Data
1:30 – 4:30 pm Exhibitor Workshops
Monday, March 28
9:00 – 11:00 am Opening Session/Keynote Address
11:00 am – 6:30 pm Exhibit Hall Open
11:30 am – 1:00 pm Poster Session 1 and Lunch in the Exhibit Hall
1:30 – 4:30 pm Technical Sessions
»» Track I: Session 1: SLAS Session: Next Generation Technologies: Microfluidics
»» Track II: Session 1: Translational Research: Resources and Collaborative Paradigms
in Academia, Not-for-Profit and Industry
»» Track III: Session 1: Target Resuscitation: Drug Repositioning Opportunities
5:00 – 6:30 pm Welcome Reception in the Exhibit Hall
Tuesday, March 29
8:00 – 8:45 am Exhibitor Tutorials
9:00 am – 12:00 pm Technical Sessions
»» Track I: Session 2: Innovations in Screening Biology: Assays, Techniques
and Instrumentation
»» Track II: Session 2: Government, Foundation, NGO and Industry Funded Research
Initiatives
»» Track III: Session 2: Target Mining:Interpretation and Annotation, Data Analysis,
Deorphaning
12:00 – 4:30 pm Exhibit Hall Open

12:00 – 1:30 pm Poster Session 2 and Lunch in the Exhibit Hall
12:30 – 1:15 pm Exhibitor Tutorials
2:00 – 4:00 pm Special Interest Groups (SIGs)
Wednesday, March 30
8:00 – 8:45 am Exhibitor Tutorials
»» Track I: Session 3: Critical Reagents and Technologies in HTS to Lead Efforts
»» Track II: Session 3: Molecular Discovery in Non-Traditional, Neglected
and Rare Diseases
»» Track III: Session 3: Applications in Consumer Products, Cosmetics, Nutraceuticals
and Agriculture
12:00 – 5:30 pm Exhibit Hall Open

12:00 – 1:30 pm Poster Session 3 and Lunch in the Exhibit Hall
2:00 – 4:30 pm Technical Sessions
»» Track I: Session 4: Innovations in Label Free, Multiplexed and High Content Assays
»» Track II: Session 4: Case Studies for HotTargets: From the Lab to Lead Compounds
»» Track III: Session 4: Tools for Drug Target Validation: RNAi, cDNA, Peptides and
Structural Biology
4:30 – 5:30 pm Reception in the Exhibit Hall

7:00 – 10:00 pm Conference Networking Reception at Gaylord Palms Hotel
Thursday, March 31
»» Track I: Session 5: Innovations in Screening and Sample Management: Technologies
and Processes
»» Track II: Session 5: Translational Research
»» Track III: Session 5: Prediction and Elucidation of Target Liabilities
12:00 – 1:30 pm Closing Luncheon and Keynote Presentation
Join the SLAS Social Media Communities

Our online communities are growing every day. Stay up-to-date
and join in the discussions. Sign-up now!
What’s New and Exciting for SBS 2011
During this five-day event more than 2,000 scientists, innovators, researchers and industry
analysts from around the globe gather in Orlando to learn about the latest trends and basic
and applied research that are transforming the way new pharmaceuticals are developed.
SBS 2011 offers:

• 15 Diverse Scientific Sessions Organized Into Three Tracks:
»» Innovations in the Screening Sciences
»» Translational Research
»» Sequenced Genomes: Reducing Opportunities to Practice
• Engaging Keynote Presentations

SBS Achievement Award winner Robert J. Lefkowitz, M.D., Duke University, and SBS Accomplishment
Award winner Brian Shoichet, Ph.D., University of California, San Francisco, and Hugh Rosen, M.D., Ph.D.,
The Scripps Research Institute
• Enhanced Exhibit Hall Hours and Schedule

Allows for a thriving exhibit floor with leading companies from around the world.
• SLAS Smart-Savers Discount Program

Offers extraordinary discounts on flights, registration, hotel accommodations, and more.
• Enhanced SLAS Career Connections

Provides a forum for job seekers and employers to connect, and career
coaches offering free coaching services to participants by appointment.
• SLAS New Product Award Designation
Recognizes up to three of the best and most promising new products launched on the exhibit floor.
Short Course Program Overview
Sunday, March 27
8:30 am – 5:00 pm
Automated Assays for Drug Discovery: A Toolbox
Approach to Selecting an Appropriate Assay
This course focuses on one central question: given a multitude of assay
technologies available for a given target, how does one go about selecting an
appropriate technology? What criteria should one examine during this process?
This course describes a toolbox approach—a generic, flexible set of assay
methodologies and shows how they can be applied to some of the major target
classes in molecular and cell-based screening. Assay case studies are presented,
and course participants will engage in discussions of toolbox formats comparing
the robustness of different assays as well as cost and user-friendliness.
Objectives
This course reviews various state-of-the-art assay and detection technologies
available for development and implementation of molecular and cell-based assays
for accelerated drug discovery. Emphasis is placed on generic assay formats that
can be applied to a variety of target types—the Assay Toolbox. Specifically, it
provides theoretical background and best practices for the design, development
and implementation of automated assays for kinases, proteases, GPCRs, protein-
protein interactions, receptor-ligand binding, and other target classes of interest.
Who Would Benefit From This Course
The SBS 2011 Short Course Individuals involved in assay development at any level.
Program offers rapid introduction
Instructors
to, or relevant refresher on,
E. Michael August, Boehringer-Ingelheim Pharmaceuticals, Inc. (Lead instructor);
important drug discovery topics.
Mohammed Kashem, Boehringer-Ingelheim Pharmaceuticals, Inc.; Siqi Lin,
Led by distinguished faculty Boehringer-Ingelheim Pharmaceuticals, Inc.
with deep expertise in their
respective course topic, SBS
short courses offer practical BacMam101: Practical Aspects of Making and Using
training. Held on Sunday prior to BacMam Vectors
the Monday opening of the main BacMam engineered recombinant baculovirus vectors can efficiently deliver expression
technical program, participants cassettes to a wide variety of mammalian cell types. The ease of generation, the safety
can attend the short course and the unparalleled experimental versatility of BacMam vectors makes transient gene
program without missing a delivery in support of cell-based assays a viable option for high-throughput screening.
moment of the 17th Annual This course covers basic practical aspects of vector generation and provides detailed
SBS Conference and Exhibition. instruction on how to optimally utilize BacMam vectors for development and support of
cell-based assays. There is plenty of time available during the class for discussion as
well as Q&A. The course describes the basic principles of viral generation, insect cell
Short Courses are not included culture and recombinant baculovirus growth procedures as well as provides details of
in the full conference registration how to develop BacMam based assays.
fee. For short course pricing see Objectives
page 22. Specific objectives of this course include:
1. Introduction to Baculovirus and design of recombinant baculoviral vectors
2. Methods for production of recombinant baculoviral vectors
3. BacMam assay design and optimization
4. Biosafety of BacMam vectors
5. Commercially available BacMam resources
Current users of the technology as well as those wishing to learn how they might
implement BacMam technology in their own laboratory would benefit from this course.
Instructors
Robert Ames, GlaxoSmithKline (Lead Instructor); Frederick M. Boyce, Massachusetts
General Hospital; Jim Fornwalkd, GlaxoSmithKline; Patrick Condreay, GlaxoSmithKline;
Christopher Kemp, Kempbio, Inc.; George Handsen, Life Technologies
Establishing Cell-Based Assays for Screening Label-Free/Biophysics Methods for Screening

Cell-based assays are essential tools in the drug-discovery Biophysical/label-free methods are becoming important tools
industry. They are important in high-throughput screening as in lead finding and drug discovery, complementing, but not
well as target identification and secondary compound profiling. replacing, more classical assay technologies. A collection of
Selecting the most appropriate assay from the large number long-standing, “gold-standard” label-free methods is rapidly
available and establishing that assay within a minimal time being augmented by novel, higher throughput techniques,
frame are critical to a project’s success. This course begins presenting both an extensive but also confusing landscape
with an overview of critical factors to consider for selection, of biophysics tools in drug discovery. A key question is how
maintenance, and characterization of cells necessary to to enable efficient and more systematic use of the biophysics
develop successful cell-based assays for HTS. portfolio in early drug-discovery programs. Ultimately they
Specific application examples covered by individual are expected to offer not only novel ways of hit finding, but
instructors include: also more efficient ways to identify and advance true hits for
1. An overview of cell viability, cytotoxicity, and apoptosis chemistry and later stage biology. This course focuses on
assays including multiplexing with genetic reporters biophysics technologies with highest impact and applicability
2. The scale-up and use of frozen cells for GPCR assays such for screening and lead finding (e.g., protein thermal denaturation
as cAMP, cellular reporters, calcium mobilization or label-free and aggregation [DSF aka Thermofluor, DSLS aka Stargazer,
electrical impedance measurements Atlas]; SPR, interferometry and waveguide grating [e.g. SPR aka
3. An overview of the application and use of RNAi technology Biacore, Corning Epic, SRU BIND, Fortebio]; NMR; calorimetry
for screening (DSC, ITC); affinity mass spectrometry; dynamic light scattering.
Objectives Objectives
The course objective includes teaching the student the basic Provide an overview on the most relevant biophysics/label-
strategy and methodology for conducting cell-based assays free technologies for screening and lead finding. This course
and providing a toolbox for picking assays appropriate for a includes teaching the basic strategy of the technologies,
particular need based on evaluations of the advantages and discussing key applications in screening/lead finding projects
disadvantages of each method. and their use in the light of impact but also limitations.
Showcases help the attendee to better judge how to make
best use of this quite novel technology toolbox in their
All levels from beginner to intermediate to advanced developing individual projects.
cell-based assays for screening.
Instructor
Individuals interested in getting an overview about the current
Terry Riss, Promega Corporation (Lead Instructor) broad biophysics/label-free portfolio in lead finding, but
certainly all persons involved in the field who want to learn
about concepts and applications of their “best practice.”
In Vitro ADME Screening: Basic Concepts This course is directed towards attendees from both
and Practical Methods industry and academia. However, due to the vast variety of
This course covers principles and methods of in vitro ADME potential label-free methods and applications, the focus is
(Absorption, Distribution, Metabolism and Excretion) testing. on technologies suitable in a typical screening/lead-finding
Selected topics include solubility, plasma protein binding, environment of early drug discovery.
absorption including Caco-2, metabolic stability, cytochrome
Instructor
P450 inhibition and induction.
Johannes Ottl, Novartis Pharma NIBR
Objectives
Attendees of this course gain an understanding of basic
concepts and methods for in vitro ADME testing. In addition,
attendees learn how to interpret test findings, with the aim
of selecting small molecule drug candidates with favorable
pharmacokinetic properties. The merits of selected common
and more recent approaches are examined.
Individuals with little or no exposure to ADME concepts
benefit from this course. More experienced individuals seeking
“refresher” training or exposure to alternate views also benefit.
Expected participants include synthetic chemists, nonclinical
and clinical scientists, individuals from regulatory agencies
and project team leaders.
Instructors
Charles L. Crespi, Becton Dickinson and Company (Lead
Instructor); Anshul Gupta, AstraZeneca; Michael Rooney,
AstraZeneca; David Stresser, BD Biosciences
Statistical Methods for In Vitro Assays High-Content Screening

in Drug Discovery High-content screening is a powerful technology platform
The course covers a set of statistical methods that are for implementing functional cell-based assays that allow
useful for designing, optimizing, validating, and analyzing truly multiparametric analysis in the physiological context
in vitro biological assays for use in drug-discovery research. of intact cells. This course provides a state-of-the-art overview
Covered topics will include Z’factor, false positive/negative of the components of HCS (instrumentation, fluorescent labels,
rates, dose-response curve fitting, minimum significant ratio, HC assay development, automated image analysis and
control charting, correlation, and statistical experimental multi-parametric data analysis) together with some showcases
design. of small molecule and RNAi high-content screens in industry
and academia.
Objectives
Objectives
Upon completion of this course, participants are able to:
1. Understand and apply common assay performance Teach the basics relevant to high-content screening and
measures provide an overview on the toolbox (instrumentation, reagents,
2. Calculate false positive and false negative rates for image and data analysis). Explore special aspects in assay
high-throughput screening assays development for HCS. Present showcases to discuss assay
3. Understand and apply appropriate statistical methods selection, screening and hit verification strategies.
for estimating potency values Who Would Benefit From This Course
4. Determine the reproducibility of potency assays using
Both beginners as well as experienced persons wishing
the minimum significant ratio (MSR) and control charting
5. Apply correlation analysis to understand flow scheme to be refreshed on some aspects of HCS and more recent
connectivity developments would greatly benefit. This course is directed
6. Understand the basic concepts of statistical experimental towards attendees from both industry and academia.
design for optimizing assays
This course is targeted to individuals interested in developing
in vitro biological assays and use of these assays in drug
discovery.
Instructor
Viswanath Devanarayan, Abbott Laboratories, GPRD
Join SLAS and Save Big On SBS 2011

Did you know that by becoming a member of SLAS and registering for
SBS 2011 with the member discount, you will save significantly more
money than you would if you registered for SBS 2011 as a non-member?
Join SLAS now at SLAS.org and save big on SBS 2011!
Keynote Speakers
Thought-Provoking Keynote Presentations

Thought-provoking presentations by impressive scientific pacesetters offer personal insights into innovation
and achievement. Learn from them and be inspired by them.
Monday, March 28, 9:00 – 11:00 am

SBS Achievement Award Winner
Robert J. Lefkowitz, M.D., Duke University School of Medicine, Durham, North Carolina
Beta Arrestin Mediated Signaling by 7 Transmembrane Receptors: New Therapeutic Opportunities

Robert J. Lefkowitz studies receptor biology and signal transduction and is best known for his detailed
characterizations of the sequence, structure and function of the beta-adrenergic receptor and the proteins
required for its regulation. Upon recognizing the sequence and functional homology with the visual protein
rhodopsin, Dr. Lefkowitz proposed that adrenergic receptors and rhodopsin were related and the first
members of a new protein family, the seven transmembrane receptors or G-protein coupled receptors.
This superfamily is now known to be the largest, most diverse, and most therapeutically accessible. Author
or co-author of more than 800 publications, Dr. Lefkowitz is among the most highly cited researchers in the
fields of biology, biochemistry, pharmacology, toxicology, and clinical medicine according to Thomson-ISI.
SBS Accomplishment Award Winner

Brian Shoichet, Ph.D., University of California, San Francisco, San Francisco, California
Mechanism and Effects of Colloidal Aggregation in Early Discovery and Drug Pharmacology
Research in the Shoichet Lab at the University of California, San Francisco seeks to bring chemical
reagents to biology, using a combination of computational simulation and experiment. Using a protein-
centric approach, new ligands are sought to complement protein structures. This typically involves
molecular docking and the development of model experimental systems to experimentally test new
algorithms. A new direction adopts a ligand-centric approach that seeks new targets for known drugs
and reagents. Whereas this lacks the physical foundation of structure-based docking, it returns to an
older, pharmacological view of biological relationships, bringing to it a quantitative model. A biological
focus for both areas is the discovery of reagents to modulate GPCRs. This research is supported by the
National Institutes of Health.
Thursday, March 31, 12:00 – 1:30 pm
Hugh Rosen, M.D., Ph.D., The Scripps Research Institute, Scripps, Florida
Allostery and S1P Receptors: A Syzygy of Pharmacology and High-Resolution Crystal Structure
Approaches to S1P1 receptor therapeutics will be presented, including uHTS approaches, pharmacological
clues for allostery, pocket mapping by mutagenesis, insights from a high-resolution S1P1 crystal structure,
implications for signal bias and the biological consequences of receptor modulation.
Technical Session Program Overview
Track I: Innovations in the Screening Sciences

To stand still is to lose ground; innovation in High-Throughput Screening Technologies (HTS) is exploding. This track
captures the excitement in all aspects of HTS. See what’s new in screening automation, instrumentation, detection
technologies and sample management.
Track II: Translational Research

Well established as an essential tool in industry, the screening sciences have been embraced by academic institutions,
not-for-profit organizations, government-funded labs and non-government organizations (NGOs). These organizations
complement the work done in industry or form cross-functional patnerships to achieve transcendent goals. Come and
hear how this shift is changing research and the relations between industry, government and academia.
Track III: Sequenced Genomes: Reducing Opportunities to Practice

The availability of sequenced genomes and the inevitability of inexpensive phenotyping have created huge opportunities
in therapeutic agents and consumer products discovery. Come and share how and why screening sciences are ideally
positioned to take advantage of these opportunities.
Please check the website often—SLAS.org/events/sbs11—for the most up-to-date information regarding SBS 2011 in Orlando.
Monday, March 28 Schedule subject to change
Track I » Session 1: SLAS Session: Next Generation Technologies:

1:30 – 4:30 pm Microfluidics
Session Chairs: Bill Janzen, University of North Carolina at Chapel Hill and
Scott Martin, St. Louis University
Plenary: Micro- and Nanofluidic Devices: Acquiring Chemical and Biochemical Information
1:30 – 2:00 pm
Quickly From Small Quantities of Material; Michael Ramsey, University of North Carolina, Chapel Hill
Enhanced Information From Microtiter Plate Screening by Scanning Wells Integrated Into
2:00 – 2:30 pm
Microfluidic Devices; Dana M. Spence, Michigan State University, United States
Micro- and Nanofluidic Devices for Cancer Screening and Virus Sensing; Stephen Jacobson,
3:00 – 3:30 pm
Indiana University
Perfusion Culture Microchamber Array Chip for High-Throughput Cell-Based Assays;
3:30 – 4:00 pm
Shinji Sugiura, National Institute of Advanced Industrial Science and Technology (AIST)
Well Plate Microfluidic Devices for Investigation of Dynamic Platelet Behavior Under Variable
4:00 – 4:30 pm
Shear Loads; Carolyn Conant, Fluxion Biosciences
Track II » Session 1: Translational Research: Resources and Collaborative
1:30 – 4:30 pm Paradigms in Academia, Not-for-Profit and Industry
Session Chair: Paul Burn, Sanford Research Center
1:30 – 2:00 pm Plenary: Putting Research Into Practice; Paul Burn, Sanford Research Center
Changing the Rules for the Research “Game” in Academia—Accelerating Discovery Through
2:00 – 2:30 pm
Novel Means of Collaboration; Mark Atkinson, The University of Florida
Collaboration as a Central Strategy for Successful Translational Research; John Reed,
3:00 – 3:30 pm
Sanford-Burnham Medical Research Institute
Challenges and Successes of Translational Research in the Public Domain: Retrospective and
3:30 – 4:00 pm Prospective Analyses and Case Histories of “Probes to Leads” From Six Years of the Molecular
Libraries Program; Stefan Vasile, Conrad Prebys Center for Chemical Genomics at Lake Nona
4:00 – 4:30 pm Translation in Action: MRCT's Centre for Therapeutics Discovery; Justin Bryans, MRC Technology
SLAS.org/events/sbs11 | 11
1:30 – 4:30 pm
Track III » Session 1: Target Resuscitation: Drug Repositioning Opportunities
Session Chair: Roger Bosse, PerkinElmer
Plenary: Drug Repositioning: How it Fits With Current Drug-Discovery Trends;
1:30 – 2:00 pm
Christopher A. Lipinski, Melior Discovery
Prodrugs: Regulatory and Clinical Development Requirements For Approval; Ken Phelps,
2:00 – 2:30 pm
Camargo Pharmaceutical Services, LLC
3:00 – 3:30 pm Michel Bouvier, University of Montreal
A Rapid Assay for Identifying New Drug Candidates From Approved Drugs for Repositioning
3:30 – 4:00 pm
to Treat Giardiasis; Catherine Chen, NIH Chemical Genomics Center
Tuesday, March 29
Track I » Session 2: Innovations in Screening Biology: Assays, Techniques
9:00 am – 12:00 pm and Instrumentation
Session Chair: Jonathan O’Connell, Bristol-Myers Squibb Company
Plenary: The Evolution of HTS at Bristol-Myers Squibb: Enabling the Support of the Most Relevant
9:00 – 9:30 am
Bio-Assays; Jonathan O’Connell, Bristol-Myers Squibb Company
Etv6-NTRK3, A Constitutively Active Tyrosine Kinase Found in Variety of Tumors, is Unique
9:30 – 10:00 am
in its Mechanism of Transformation; Jack Allen, Merrimack Pharmaceuticals
High-Throughput Screening With Real-Time PCR: Reducing it to Practice; Andrea Weston,
10:30 – 11:00 am
Bristol-Myers Squibb Company
New Ion Channel Screening Technologies Enabling Development of High Quality and
11:00 – 11:30 am
High-Throughput Assays in a Plate-Based Screening Group; Juha Kammonen, Pfizer
Creating a Holistic Screening Strategy for Label-Free Technology in a Plate Based Screening
11:30 am – 12:00 pm
Group; Rachel Russell, Pfizer Global Research & Development
Track II » Session 2: Government, Foundation, NGO and Industry Funded
9:00 am – 12:00 pm Research Initiatives
Session Chair: Ken Duncan, Bill and Melinda Gates Foundation
Plenary: Drug Discovery Focused on Neglected Diseases Through Initiatives Funded by
9:00 – 9:30 am
Governments, Foundations and Private Donors; Ken Duncan, Bill and Melinda Gates Foundation
9:30 – 10:00 am The Importance of Metabolic Status to Tuberculosis Drug Discovery; Clifton Barry, NIAID, NIH
10:30 – 11:00 am Screening for Novel Antimalarials; R. Kip Guy, St. Jude Children’s Research Hospital
Cancer Research Technology: Bridging the Industry-Academia Interface in Oncology;
11:00 – 11:30 am
Tim Hammonds, Cancer Research Technology
Simultaneous Screening of a Large Natural Product Library Against a Panel of 10 Anti-Apoptotic
11:30 am – 12:00 pm Proteins in Search of Novel Cancer Therapeutics; Paul Diaz, Sanford-Burnham Medical Research
Institute
Track III » Session 2: Target Mining: Interpretation and Annotation,
9:00 am – 12:00 pm Data Analysis, Deorphaning
Session Chair: Andrew Su, Genomics Institute of the Novartis Research Foundation
Plenary: The Gene Wiki: Crowdsourcing Knowledge Extraction From the Biomedical Literature;
9:00 – 9:30 am
Andrew Su, Genomics Institute of the Novartis Research Foundation
Systems and Personalized Medicine; Atul Butte, Stanford University and Lucile Packard Children’s
9:30 – 10:00 am
Hospital
Causal Reasoning on Biological Networks: Interpreting Transcriptional Changes; Daniel Ziemek,
10:30 – 11:00 am
Pfizer Worldwide Research and Development
Drug Effects Viewed From a Protein Network Perspective; William Loging,
11:00 – 11:30 am
Ingelheim Pharmaceuticals, Inc.
Wednesday, March 30
Track I » Session 3: Critical Reagents and Technologies in HTS to Lead Efforts
9:00 am – 12:00 pm Session Chairs: Ulrich Schopfer, Novartis Institutes for BioMedical Research and
Achim Grenz, F. Hoffman-La Roche Ltd
Plenary: Bridging the Gap Between Phenotypic Screens and Molecular Targets;
9:00 – 9:30 am
Ulrich Schopfer, Novartis Institute for BioMedical Research, Inc.
Identifying Helicobacter Pylori AddAB DNA Repair Enzyme Inhibitors Using a Novel Bacteriophage
9:30 – 10:00 am
E. coli Infectivity Assay in Highly Miniaturized Formats; Tim Spicer, The Scripps Research Institute
Target Identification and Validation Using Chemical and Functional Genetics Screening
10:30 – 11:00 am
Approaches; Vic Myer, Novartis Institutes for Biomedical Research, Inc.
HT RNAi Screening of Anti-Cancer Targets With Pooled shRNA Libraries; Alex Chenchik,
11:00 – 11:30 am
Cellecta, Inc.
Human “Knock-in” “Knock-out” Cell Lines for Precision Functional Genomics and Targeted
11:30 am – 12:00 pm
Drug Discovery; Chris Torrance, Horizon Discovery Ltd, IQ Cambridge
Track II » Session 3: Molecular Discovery in Non-Traditional,
9:00 am – 12:00 pm Neglected and Rare Diseases
Session Chair: Bob Hertzberg, GlaxoSmithKline
Plenary: Opening the Doors and Giving Back: GSK’s Strategy to Deliver Medicines for Diseases
9:00 – 9:30 am
of the Developing Worlds; Bob Hertzberg, GlaxoSmithKline
Throughput Screening to Identify Inhibitors of the Respiratory Chain of Mycobacterium
9:30 – 10:00 am
Tuberculosis; Khisimuzi Mdluli, Global Alliance for TB Drug Development
The Development of RNA-Modulating Therapies; Judith C.T. van Deutekom, Prosensa Therapeutics BV,
10:30 – 11:00 am
Leiden
Humanitarian and Commercial Cloud-Based Collaborative Drug Discovery; Barry Bunin,
11:00 – 11:30 am
Collaborative Drug Discovery (CDD), Inc.
Potent and Selective Inhibitors of the Plasmodium Falciparum M18 Aspartyl Aminopeptidase
11:30 am – 12:00 pm (AAP) of Human Malaria Identified via a QFRET uHTS Campaign; Virneliz Fernandez Vega,
The Scripps Research Institute, Scripps Florida
Track III » Session 3: Applications in Consumer Products, Cosmetics,
9:00 am – 12:00 pm Nutraceuticals and Agriculture
Session Chair: Sabrina Corazza, Axxam
9:00 – 9:30 am Plenary: New Frontiers for HTS Application: How and Why; Sabrina Corazza, Axxam
9:30 – 10:00 am Receptor Mediated Discovery of Novel Taste Modulators; Jay Slack, Givaudan Flavors Corp.
Insecticidal Compounds “Well” Spotted: Screening Live Bugs in a High-Throughput System;
10:30 – 11:00 am
Juergen Langewald, BASF
11:00 – 11:30 am Anthony J. Clark, PepsiCo
Track I » Session 4: Innovations in Label-Free, Multiplexed and
2:00 – 4:30 pm High-Content Assays
Session Chair: James Inglese, NIH Chemical Genomics Center
Plenary: Quantitative High-Throughput Screening of Phenotypic Assays Enabled by Laser-
2:00 – 2:30 pm
Scanning-Coupled Microscopy; James Inglese, NIH Chemical Genomics Center
2:30 – 3:00 pm Jeffrey Price, Sanford Burnham
Binding Assays in Biological Liquids Using Microscale Thermophoresis; Stefan Duhr, NanoTemper
3:00 – 3:30 pm
Technologies
Use of Label-Free Technology to Monitor GPCR Desensitization; Patricia McDonald,
3:30 – 4:00 pm
Scripps Research Institute
Enabling Lead Discovery at Epigenetics Targets With RapidFire Mass Spectrometry;
4:00 – 4:30 pm
Melanie Leveridge, GlaxoSmithKline
Track II » Session 4: Development of Novel Anti-Cancer Therapeutics

2:00 – 4:30 pm that Reduce Tumor-Initiating Cell Frequency
Session Chair: Phillip Tagari, Amgen
Plenary: Inhibitors of 2-OG Oxygenases for the Treatment of Anemia and Cancer;
2:00 – 2:30 pm
Phillip Tagari, Amgen
Cancer Drug Discovery: A Target Class Approach to Histone Methyltransferases;
2:30 – 3:00 pm
Mike Moyer, EpiZyme, Inc.
Identification and Characterization of Potent and Selective Antagonists of the Nuclear Receptor
3:00 – 3:30 pm
RORc; Gary Glick, Lycera Corporation
3:30 – 4:00 pm Targeting the Ubiquitin Pathway: Beyond the Proteasome; Craig Allan Leach, Progenra Inc.
Development of Novel Anti-Cancer Therapeutics that Reduce Tumor-Initiating Cell Frequency;
4:00 – 4:30 pm
Tim Hoey, OncoMed Pharmaceuticals, Inc.
Track III » Session 4: Tools for Drug Target Validation: RNAi, cDNA,
2:00 – 4:30 pm Peptides and Structural Biology
Session Chair: Daniel Sipes, Genomics Institute of the Novartis Research Foundation
Expanding the Utility of Miniaturized HTS: From Screening to Profiling and Target Identification;
2:00 – 2:30 pm
Daniel Sipes, Genomics Institute of the Novartis Research Foundation
Technologies Recently Developed for the Determination of the Cellular Activity of Small
2:30 – 3:00 pm
Molecules; Frederick J. King, The Novartis Institutes for Biomedical Research
Now What? Approaches to Following Up Large-Scale Screening; John Hogenesch,
3:00 – 3:30 pm
University of Pennsylvania
Parallel Small-Scale Expression and ELT Screening of Drug Targets to Explore Druggability
3:30 – 4:00 pm
and Generate Chemical Probes; Jeffrey Gross, GlaxoSmithKline
4:00 – 4:30 pm Target Validation Strategies for Protease Research; Lorenz Mayr, Novartis Pharma AG
Thursday, March 31
Track I » Session 5: Innovations in Screening and Sample Management:
9:00 am – 12:00 pm Technologies and Processes
Session Chair: Claude DuFresne, Merck
9:00 – 9:30 am Claude DuFresne, Merck
The Impact of Non-Contact Picoliter Dispense Technology in the Elimination of Serial Dilution;
9:30 – 10:00 am
Daniel Thomas, GlaxoSmithKline
Labware Leachables: Do You Know What’s In Your Assay Well?; John Watson, Bristol-Myers
10:30 – 11:00 am
Squibb R&D
11:00 – 11:30 am Investigating the Stability of High Concentration DMSO Solutions; Ioana Popa-Burke, GlaxoSmithKline
The Optimization of Instrumentation, Workflow and Data Analysis for In Vitro ADME Assays:
11:30 am – 12:00 pm
A Business Case; Thomas Arnhold, Boehringer Ingelheim Pharma GmbH and Co KG
9:00 am – 12:00 pm Track II » Session 5: Translational Research (Visit SLAS.org/events/sbs11 for speaker updates.)
9:00 am – 12:00 pm
Track III » Session 5: Prediction and Elucidation of Target Liabilities
Session Chair: Keith Houck, Environmental Protection Agency
Plenary: Elucidation of Adverse Bioactivity Profiles as Predictors of Toxicity Potential;
9:00 – 9:30 am
Keith Houck, Environmental Protection Agency
Utilities of In Vitro Safety Pharmacology in Early Drug Discovery: Mitigation of ADRs;
9:30 – 10:00 am
Laszlo Urban, Novartis Institutes for Biomedical Research
From Data to Knowledge: Integration of Compound Structure and Activity With Clinical ADRs;
10:30 – 11:00 am
Eugen Lounkine, Novartis Institutes for Biomedical Research
In Silico Modeling for Predicting In Vivo Kinetics and Toxicity During Drug Discovery;
11:00 – 11:30 am
Simon Thomas, Cyprotex Discovery Ltd
Identification of Systemic Toxicity Triggers Associated With VEGF-R Inhibitors; Hisham Hamadeh,
11:30 am – 12:00pm
Amgen Inc.
Special Educational Sessions
Sunday, March 27, 1:00 – 4:00 pm

BioAssay Ontology: Development of an Industry Standard
for the Description and Categorization of Small Molecule
High-Throughput Screening Data
Presenters: Stephan Schürer, University of Miami;
Vance Lemmon, University of Miami
Job Seekers
Large and diverse data sets that are generated in high-throughput SLAS Career Connections at SBS 2011 provides
screening (HTS) campaigns in industry, non-profit, and academic job seekers a means to browse the job boards,
organizations are presently difficult to explore. We have begun to and network with recruiting professionals.
develop a bioassay ontology and software tools to formalize the
knowledge in HTS data sets in order to facilitate their analysis and • Online Résumé Submission
integration with other databases. This interactive program presents • Connect With Employers Also Attending SBS 2011
the progress that has been made to date, demonstrate software that • Search Jobs Available At SBS 2011
we have developed and seek feedback from the community. Individuals • Free! One-to-One Career Coaching Sessions
interested in assay standards, analysis and integration of HTS results
should participate. This project is supported by a grant from the Employers
National Human Genome Research Institute.
Your company can conduct highly confidential
and professional in-person interviews, and have
a major presence in an informal setting that nurtures
Monday, March 28, 7:00 – 9:00 am networking and relationship building. SBS 2011
Analytical and Life Science Systems Association (ALSSA) posting packages are available.
This exclusive invitation-only briefing assesses several recent • Special Job Posting Rates Available for SBS 2011
developments and trends in laboratory automation technologies • Private Interview Space Available
and applications and the strategic implications for users and • Access to over 2,000 SBS 2011 participants
suppliers. Featured speakers include senior level executives
• Enhanced Career Coaching Services at SBS 2011
from customers and users from both the pharma and food
• Marshall Brown and Associates partners with
processing industries.
SLAS to provide FREE services
Tuesday, March 29, 1:15 – 2:15 pm Monday – Tuesday, March 28 – 29

In response to the constricting job market
SLAS Strategic Plan Meeting around the world, SLAS introduces SLAS Career
Successful organizations require a strategic plan founded in Connections, Career advisor Marshall Brown, PCC,
sound, systematic and rational principles, and supported by of Marshall Brown and Associates, Washington, D.C.
diligent implementation, monitoring and evaluation. As the first will staff SLAS Career Connections at SBS 2011.
step in establishing results-based accountability for the future Together with colleague Alan De Back, Marshall
growth of SLAS, the SLAS Strategic Plan Working Group began Brown will provide professional and discrete career
by addressing these essential points: Where are we; what do we have services for SBS 2011 participants. Career advisors
to work with; where do we want to be; and how do we get there? are on hand for private, one-to-one dedicated time
For the past several months, the Working Group and SLAS to conduct mock interviews, review résumés, provide
professional team members researched, debated, developed and coaching and networking guidance, and strategize
ultimately documented this inaugural strategic plan. The SLAS market opportunities with job seekers and hiring
Board of Directors then took its turn considering, discussing and managers. This is a free service.
debating the plan before unanimously approving it in September.
As a member-driven society, however, our work is just beginning. Get Started Today! Create an Account at
SLAS.org/events/sbs11/careerconnections.cfm
This plan is not a rigid step-by-step recipe of next steps. It is
a multi-dimensional context that will guide our decisions and a
framework to measure our progress in the months and years ahead.
Because this is a major time of transition for our newly formed Maximize Your Conference Experience
organization, we expect many elements and pressures to impact Through Effective Networking
the organization, however, continued adherence to this plan will Monday, March 28, 8 – 9 am
ensure that our focus remains true to our mission and goals.
Learn how to best and most effectively utilize your
With this in mind, members of the Strategic Plan Working Group, time by connecting with the right people at SBS 2011.
Board of Directors, and the professional team need to hear from This session looks at key strategies for developing
you—the SLAS members. Please take advantage of this meeting personal business relationships that help you get
things done, make connections and build a strong
opportunity to voice your ideas and perspective to help us further
framework for your career success.
refine this first-ever SLAS strategic plan.
Special Interest Groups
SBS 2011 Special Interest Groups (SIGs) are where important discussions happen. There is no fee to attend
SIG meetings. For additional information on the Special Interest Groups visit SLAS.org/events/sbs11.
Tuesday, March 29, 2:00 – 4:00 pm

Academic Outreach of microplates on behalf of and for acceptance by the
American National Standards Institute (ANSI). Once such
Chair: Sandra Nelson, University of Cincinnati
standards are approved by the MSWG, they are presented
The mission of the Academic Outreach Committee is to to the BSS Executive Council for approval and submission
foster greater interaction among academia, government, to ANSI. Participation in this SLAS working group is open to
pharmaceutical research companies and suppliers. In all interested parties directly and materially affected by its
keeping with that mission, the Academic Outreach SIG activities, including nonmembers of SLAS.
provides a venue for academics to meet and exchange
ideas, common problems and solutions. Sample Management
Chairs: Richard Kuo, Novartis; Timothy Dawes, Genetech, Inc.
ADMET
The Sample Management SIG provides a forum for discussing
Chair: Charles Crespi, BD Biosciences
sample library management issues in the modern drug-
The mission of the Absorption, Distribution, Metabolism discovery high-throughput screening laboratory. Sample
and Toxicology SIG is to advance drug discovery and libraries include discrete compounds, defined compound
development by promoting the discussion and dissemination mixtures, natural product extracts, and biologics (tissues,
of principles, topics and ideas for the integration of higher cells, DNA, RNA, and antibodies). Topics of critical importance
throughput technologies with methods for determining toxicity, include issues involved in Sample Collection; Materials
pharma-cokinetics and metabolism. The goal is to accelerate Management; and Instrumentation and Laboratory Automation.
the drug-discovery pipeline and shorten the time of the
development of new drugs that cure illnesses and improve Screen Design and Assay Technology
quality of life. This special interest group creates a bridge
Chair: Kenda Evans, PerkinElmer
and network between scientists working in the fields of
preclinical research, pharmacology, pharmacokinetics and The goals of the Screen Design and Assay SIG are to: share
those who are the producers of combinatorial libraries. current best practices and experiences in the design of screens
for high- and ultra high-throughput screening programs;
Automation Quality Control provide a platform to encourage an open discussion among
group members of any new screening technologies that can be
Chairs: John Thomas Bradshaw, Artel;
beneficial to the screening community; encourage academic
Jack Dawson, HighRezs Biosolutions
and industrial members to actively contribute to the SIG;
The Automation Quality Control SIG provides a forum for identify any gaps in reagent(s) and instrumentation and/or in the
discussion of topics relating to optimizing performances screening environment, and seek to influence the appropriate
of laboratory instrumentation. The objective is to encourage supplier(s); and evaluate new technologies and instruments on
development of procedures that should be of interest to a voluntary basis and share findings at technology-based user
instrument vendors and practitioners alike. group meetings on a more frequent basis.
Data and Image Analysis Stem Cells in Drug Discovery

Chair: Chip Allee, Ceutical Soft, Inc.; Co-Chair: Mann Shoffner, Chairs: Marcie Glicksman, Harvard NeuroDiscovery Center;
SRU Biosystem Sitta Sittampalam, University of Kansas Medical Center
The Data and Image Analysis SIG is dedicated to sharing The mission of the Stem Cells in Drug Discovery SIG is to
best practices, experiences and expertise, and to encouraging promote the discussion and dissemination of information
collaboration. The group will actively address issues in the on new enabling technologies related to the use of stem
area of information technology and strategies and foster cells and primary cells in drug discovery. We will discuss
discussions, information sharing and meetings among current developments in stem cell biology, human and mouse
group members. pluripotent stem cells, and reprogrammed stem cells. This
group will function to create a bridge between the network
Microplate Standards of scientists working in the fields of regenerative medicine,
Chairs: Amer El-Hage, Beeston Engineering; Michael Shanler, stem cell biology, chemical biology and drug discovery.
BD Biosciences
The Microplate Standards SIG exists to recommend, develop
and maintain standards to facilitate automated processing
Exhibition
Get up close and personal with more than 150 exhibitors with new technologies and techniques that are
shaping innovation and achievement in laboratories around the world. New exhibit hours ensure more than
enough time for convenient, hands-on exploration.
Don’t forget to join us for the exhibit hall receptions on Monday and Wednesday during the final hour of the
SBS 2011 exhibition. It’s a great time to visit exhibitors with whom you haven’t yet connected while enjoying
complimentary beverages and networking with friends and colleagues.
NEW Exhibit Hours for 2011!

Monday, March 28 11:00 am – 6:30 pm
Tuesday, March 29 12:00 pm – 4:30 pm
Wednesday, March 30 12:00 pm – 5:30 pm
NEW! New Product Award (NPA) Designations at SBS 2011

to Recognize Best New Products on Exhibit Floor
In the spirit of innovative excellence, each year dozens of new products launch on the SBS exhibit floor.
This year, to celebrate these breakthroughs and acknowledge the best of what’s new, the SLAS New Product
Award (NPA) designation has been introduced. At SBS 2011 in Orlando, a team of experts will select up to
three of the most promising new products launched on the exhibit floor for official SLAS NPA designation.
Poster Program
Poster presentations are a long-standing SBS conference highlight. Participants may browse through the SBS 2011 collection
of posters, located in the exhibit hall, for credible and concise examinations of new techniques and technologies from around
the world. New at SBS 2011, SLAS introduces the Student Poster Competition. Twelve applicants are selected to receive the
Travel Award in 2011. Of those selected, all are considered for the Student Poster Competition at SBS 2011, which offers cash
awards for first, second and third place for the most outstanding poster presentation.
Exhibition
Exhibitors (as of December 8)

AAT Bioquest, Inc. IDBS
ABS Inc. IDEX Health and Science
Agilent Technologies Inc. InSphero
Albany Molecular Research, IntelliCyt Corporation
Inc. International Drug Discovery
Amnis Corporation Kinaxo Biotechnologies
Art Robbins Instruments KINOMEScan
Axxam SpA Labcyte, Inc.
Beckman Coulter Lathrop Engineering Inc.
BellBrook Labs LiCONiC US, Inc.
Berthold Technologies Life Chemicals, Inc.
BIOCIUS Life Sciences Lonza
BioFocus Lumigen
BioMedTech Laboratories, matrical bioscience
Inc. MeCour Temperature
Bio-Rad Laboratories Control
Biostatus LTD. Micronic North America, LLC
BioTek Instruments, Inc. Microsonic Systems
Exhibitor Workshops Blue Sky Biotech, Inc.
BMG Labtech, Inc.
MipTec 2011
Molecular Devices
and Tutorials BPS Bioscience, Inc.
BrandTech Scientific, Inc.
MRC Technology
Naeja Pharmaceutical Inc.
Learn about the science behind the technology and how Cayman Chemical Company Nanion Technologies GmbH
to increase efficiencies in your lab. As part of the technical CCS Cell Culture Service Nexus Biosystems
program, exhibiting companies will present scientific tutorials GmbH
and workshops. Each of these is designed to give you Omni International, Inc.
Cell Signaling Technology Pall Life Sciences
an in-depth look at topics of ongoing practical interest.
Attendance is free, but space is limited, so reserve your Cellectis bioresearch PerkinElmer
space when registering. Cellular Dynamics PharmaDiagnostics NV
International
Platypus Technologies LLC
Workshops run three hours, and tutorials run 45 minutes. ChanTest Corp.
Promega Corporation
For an up-to-date listing of companies offering tutorials and ChemBridge Corporation
reinnervate, Ltd
workshops, visit our website at SLAS.org/events/sbs11. Cisbio Bioassays
ReTiSoft Inc.
Computype, Inc.
Roche
Corning Life Sciences
Companies Offering Exhibitor Workshops RTS Life Science
CYTOO Cell Architects
(as of December 8) DiscoveRx Corporation
Sanford-Burnham Research
Institute
• Agilent Technologies, Inc. • PerkinElmer Dualsystems Biotech AG Sigma Life Science
EMD Millipore Specs
Companies Offering Exhibitor Tutorials Enamine SRU Biosystems, Inc.
(as of December 8) Essen BioScience, Inc. Tecan
Fluxion Biosciences The Automation Partnership
• Bio-Rad Laboratories • InSphero AG ForteBio, Inc. Titertek Instruments Inc.
• Cell Signaling Technology • IntelliCyt Corporation GE Healthcare Titian Software Ltd
• Cisbio Bioassays • Kinaxo Biotechnologies Genedata
• Corning Life Sciences • reinnervate TTP LabTech
GenScript Viaflo Corporation
• Fluxion Biosciences, Inc. • Roche
Greiner Bio-One Wako Pure Chemical
• GE Healthcare • RTS Life Science
Hamamatsu Corporation Industries
• Genedata • SRU Biosystems
HighRes Biosolutions Wyatt Technology
Horizon Discovery Ltd Corporation
ICx Nomadics
General Information
Orlando, Florida
Orlando is best known as a family destination with well known attractions. However, it can also be a fun
and exciting city for adults. From playing a round of golf, shopping at outlet malls, enjoying a fine-dining
experience, or visiting legendary theme parks, Orlando offers a variety of activities from which to choose.
Gaylord Palms Resort & Convention Center

SBS 17th Annual Conference and Exhibition held at the Gaylord Palms Resort in Orlando, Florida area located
next to the Walt Disney World Resort. For reservations, visit SLAS.org/events/sbs11 or call +1.407.586.0000 and
ask for the Society for Biomolecular Sciences rate.
$239 Single/Double Occupancy Deposit:

(plus mandatory $15 resort fee*): • The Gaylord Palms Resort and Convention Center
• This rate is available until Monday February 21, 2011, requires a credit card guarantee at the time of reservation.
or until the block is filled, whichever is first.
Changes and Cancellations:
• Cancellation Policy: 72 Hours prior to arrival
• All reservation changes and cancellations must be made
• Early Departures: subject to a $50 fee. Please note
through Gaylord Palms Resort and Convention Center.
that this is applicable only if you change your departure
date after check in. • To avoid being charged for one night, cancellations
must be made at least 72 hours prior to your arrival
• Gaylord Palms Resort is just 20 minutes from
date. Early departures are subject to a $50 fee.
Orlando International airport Please note that this is applicable only if you
• The resort fee of $15 per room, per night includes: change your departure date after check in.
Wireless internet access in guest rooms, atriums, and poolside;
Daily newspaper; Dasani bottled water (2 replenished daily); Group Hotel Reservations:
Access to the resort’s state-of-the-art Fitness Center;
High-speed internet access in each guest room; Local phone • Group hotel reservations are available, for more
calls up to 20 minutes ($.10/minute thereafter); Toll-free and information visit SLAS.org/events/sbs11.
credit card calls up to 20 minutes ($.10/minute thereafter);
Scheduled transportation to Walt Disney World theme parks.
General Information
Airline Reservations SLAS Creates Smart-Savers Discount

You may book your air travel directly with SBS 2011’s Program for SBS 2011—Extraordinary
official travel agent, National Travel at 800.557.0842.
Discounts for Registration and Travel
Child Care Whether you are focused on continuing education and learning
the latest about drug discovery and screening, want to see and
Kid’s Nite Out is Central Florida’s number one choice for
touch the newest technologies hitting the research marketplace
professional childcare at all hotels, resorts and vacation
from around the world, or need to connect in a meaningful,
homes. Contact Shani Thompson for additional information:
face-to-face way with a colleague—SBS 2011 has everything
+1.407.828.0987; www.kidsniteout.com
you need. Spend a few moments reading about and then take
advantage of the following cost-saving programs we have
Discounted Theme Park Tickets developed for you. Join us at SBS 2011.
Bring your family to Orlando and enjoy special discounts on
admission tickets to the major theme parks. Whether you’re “Take Off With Us” Flight Discount Program
planning on arriving before the conference starts or staying The “Take Off With Us” flight discount
after the conference ends, these tickets will save you time program was created to help diminish
and money. To purchase tickets, visit SLAS.org/events/sbs11. the financial impact of travel costs
for individuals interested in exploring
drug discovery and screening at SBS
Registration Hours 2011. This mission-centric program provides $200 off the first
Registration will be located on lower level of the Gaylord Palms 50 airline tickets purchased by full-conference paid registrants.
Convention Center, in front of the Exhibit Hall. Badges and The discount applies to any airline available through the official
meeting materials can be picked up during the following times: SBS 2011 Travel Agent.
Early-Bird Registration
Saturday, March 26 2:00 – 7:00 pm An easy way to secure significant savings for SBS2011 is to
Sunday, March 27 7:00 am – 5:00 pm register early. Not only does it give you extra time to prepare for
our industry-leading conference, it gives you an opportunity to
Monday, March 28 8:00 am – 6:30 pm save up to $200 on your registration. Register by January 24,
Tuesday, March 29 8:00 am – 5:00 pm 2011 to take advantage of maximum Early-Bird registration rates.
Wednesday, March 30 8:00 am – 5:30 pm Discounted Registration for Groups

Thursday, March 31 8:00 – 11:00 am SLAS offers discounted registration to groups attending SBS
2011. Group discounts are only applicable to full-conference
registration fees and all registrations must be received by the
registration department together and from the same company/
Social Events and Networking location. Group discounts of 20% per registrant are available
Monday, March 28, 5:00 – 6:00 pm for groups of five. This discount program is only available to
registrants who pre-register and will not be available on-site.
• Welcome Reception in the Exhibit Hall
Join our manufacturing representatives in the exhibit Academic Registration Waiver
hall for hors d’ouevres and complimentary beverages, The Academic Registration Waiver was created to diffuse some
network with peers, and visit with exhibitors. of the financial pressure currently impacting the academic
community. The Waiver provides complimentary conference
Wednesday, March 30, 4:30 – 5:30 pm registration to professors and associate professors who attend
• Exhibit Hall Reception SBS 2011 with at least two pre-registered students. Student
Visit exhibitors while enjoying complimentary beverages registration for the five-day event is only $25.
and networking with friends and colleagues.
Unemployment Registration Waiver
Wednesday, March 30, 7:00 – 10:00 pm An Unemployment Registration Waiver is being offered to
• Conference Networking Reception provide complimentary SBS 2011 registration to those currently
unemployed. There is no better way to kick-start your career
Join your colleagues after dinner poolside at the and job search than to immerse yourself in career advancement
Gaylord Palms for a “Key West Night.” Desserts and search tools, as well as take advantage of numerous
and drinks are provided. professional development and networking opportunities.
Learn more about the Smart-Savers Discount

Program at SLAS.org/events/sbs11.
SBS 2011 Registration Form
Three Ways to Register: Classify Your Current Position: (check only one)
Online—Visit SLAS.org/events/sbs11 c Account Executive c Administrative
Mail—Remit payment with this form to: c Attorney/Legal c Consultant
SLAS, 11260 Roger Bacon Dr. # 500, Reston, VA 20190, USA c Director c Editor/Reporter
Fax—Send this form with complete payment c Intern c Lab Specialist
information to: c Lab Technician c Manager
+1.703.964.1246 c President/CEO c Professor
c Retired c Sales/Marketing
Attendee Information:
c Scientist/Engineer/Researcher
Please print clearly or type:
c Student c Vice President
c Dr. c Mr. c Mrs. c Ms. c Miss
Name Primary Area of Interest: (check only one)

c Bar Code Technology
Affiliation
c Biostatistics and Exploratory Data Analysis
Title c Design of Experiments (DOE)
Department c Electronic Laboratory Notebooks
c Information Technology for the Laboratory
Address
c Mass Spectrometry
City State c Microarray Applications
Zip Country c Liquid Handling
c Microfluidics
Telephone Fax
c Molecular Diagnostics
Email
c Nanobiotechnology
c Please check this box if you do not wish c Patents
to be a part of the SBS mailing list.
c Pharmacogenomics
c Project Management
Education:
c Other
c AAS c BS c MS c MD c PhD c Other
Short Courses:
Current Lab Automation Sector: (check only one)
Please choose only one. Short courses are
c Academic c Consulting c Government
an additional cost, see page 22 for pricing:
c Industry c Technology Provider c Other c Automated Assays for Drug Discovery:
A Toolbox Approach to Selecting an Appropriate Assay
Industry in Which Company Operates:
c BacMam101: Practical Aspects of Making and Using
(check only one)
BacMam Vectors
c Agriculture c Clinical Diagnostics
c Establishing Cell-Based Assays for Screening
c Consumer Products c Drug Discovery
c In Vitro ADME Screening: Basic Concepts and
c Drug Development c Energy Generation Practical Methods
and Petrochemicals
c Label-Free/Biophysics Methods for Screening
c Forensics and Security c Food
c Statistical Methods for In Vitro Assays in Drug Discovery
c Other
c High-Content Screening
Purchasing Involvement: (check only one)
c Approver/Final Decision Maker Please visit SLAS.org/events/sbs11 for more
c Not involved in buying decisions information on SBS 2011 Short Courses.
c Specifier c Influencer c Other
SBS 2011 Registration Form (continued)
Registration Full Conference Full Conference
Full Conference Short Course
Fees & Pricing* Early Member Discount Advance Registration
Late Registration (Indicate course on page 21)
Please circle applicable fee (Ends 1/24/11) (Ends 2/21/11)
Member $895 $1095 $1295 $550
Non-Member $1375 $1375 $1575 $675
Gov/Academic
Member $349 $449 $549 $265
Gov/Academic $549 $549 $699 $340

Non-Member
Student
Please fax student ID $25 $25 $25 $265
to +1.703.964.1246
One-Day Exhibit
Hall Only Free Free Free Free
(registration required)
Conference Proceedings CD: c Member $99 c Non Member $149

* Discounted Registration for Groups: SLAS offers discounted registration to groups attending SBS 2011. Group discounts are only applicable to full-conference registration
fees and all registrations must be received by the registration department together and from the same company/location. Group discounts of 20% per registrant are
available for groups of five. This discount program is only available to registrants who pre-register and will not be available on-site. Visit SLAS.org/events/sbs11.
Method of Payment:
Check Number: Check Amount:
Please make checks payable to SLAS; Send form to: 11260 Roger Bacon Dr. #500, Reston, VA 20190, USA
Credit Card: c Visa c Mastercard c Discover c AMEX
Name on Credit Card: Card Number:
Exp. Date: Authorized Amt.: Signature:
Billing address if different than above:

Name on Card:
Address: City:
State: Zip/Postal Code: Country:
Cancellation Policy
Cancellation requests received prior to Friday, February 25, 2011 will be refunded in full, less a $50 processing fee. No refunds will be issued after this date. Cancellations
must be submitted in writing to SLAS Registration at 11260 Roger Bacon Dr., #500, Reston, VA 20190, via fax at +1.703.964.1246 or via email to tsexauer@slas.org. Please
note that all refunds will be issued by check. All cancellations will be processed and refunds distributed within 30 days of the close of the conference. Registrants may
substitute another individual from within the same company and pay any difference in registration type. SLAS must be notified in writing of any substitutions.
c I agree to all terms and conditions listed below:

In Case of Emergency
This year we are asking that you please provide your cell phone number: . This number will only be used in the event of an emergency.
It will not be used for marketing purposes or stored in any way. Should an emergency arise you will receive a text message sent to the number you’ve provided.
Publicity Release
I acknowledge that at times during the SBS 2011 conference, sessions will be presented before a live audience and SLAS may web-cast, videotape, audiotape,
photograph, record or broadcast SBS 2011 or various aspects of SBS 2011. I hereby grant full permission to SLAS to use any photograph, videotape, audiotape,
motion picture, or any other similar recording or broadcast of SBS 2011 including my name and likeness for any SLAS business purpose.
SLAS Liability Waiver
I, as a conference participant, agree and acknowledge that I am undertaking such participation in SLAS events and activities of my own free will. I hereby assume all
risks of personal injury and/or other loss or damage arising out of or in any way associated with my participation in this conference. I release to the fullest extent permitted
by law, SLAS and any of its directors, officers, employees, volunteers, contractors, agents or other representatives, successors, assigns, and all others acting on their
behalf (collectively referred to herein as the “Released Parties”) from any and all responsibilities, claims, expenses, personal injury, wrongful death or liability for injuries
or damages, and expenses, including reasonable attorney’s fees and costs incurred in defending such claims directly or indirectly resulting from, or in any way arising
out of or related to my participation in this conference. I acknowledge that my participation in this conference is expressly conditioned on my agreeing to the foregoing.
Scientific Committee and SLAS Leadership
SBS 2011 Scientific SLAS Board of Directors

Committee Michelle Palmer, Ph.D., Broad Institute of Harvard and MIT
Jason Abbas, M.S., Syngenta Seeds
Program Chairs Robert Ames, Ph.D., GlaxoSmithKline

David Dorsett, M.B.A., Bristol-Myers Squibb Company
Bill Janzen, Ph.D., University of North Carolina - Chapel Hill
Paul Bernasconi, Ph.D. Jeff Paslay, Ph.D., Paslay Consulting
BASF Corporation Erik Rubin, Ph.D., Bristol-Myers Squibb Company
Mary Jo Wildey, Ph.D., Merck Research Labs
Andy Zaayenga, Ph.D., HighRes Biosolutions
Peter Hodder, Ph.D.

The Scripps Research Institute
Biomolecular Sciences
Section (BSS) Executive
Council
Roger Bosse, Ph.D., PerkinElmer
John Printen, Ph.D., Life Technologies
Paul Burn, Ph.D., Sanford Project
Roger Bosse, Ph.D., PerkinElmer
Sabrina Corazza, Ph.D., Axxam SpA
Sue Holland-Crimmin, Ph.D., GlaxoSmithKline
Claude DuFresne, Ph.D., Merck
Lorenz Mayr, Ph.D., Novartis Pharma
Ken Duncan, Ph.D., Bill and Melinda Gates Foundation
Steve Rees, Ph.D., GlaxoSmithKline
Achim Grenz, Ph.D., F. Hoffmann-La Roche Ltd
Melvin Reichman, Ph.D., Lankenau Institute for Medical
Bob Hertzberg, Ph.D., GlaxoSmithKline Research Chemical Genomics Center
Keith Houck, Ph.D., Environmental Protection Agency John Wang, Ph.D., Wang Consulting
Jim Inglese, Ph.D., NIH Chemical Genomics Center Maria Webb, Ph.D., Venenum Biodesign
Bill Janzen, Ph.D., University of North Carolina at Chapel Hill Andy Zaayenga, Ph.D., HighRes Biosolutions
Scott Martin, Ph.D., St. Louis University
Jonathan O’Connell, Ph.D., Bristol-Myers Squibb Company
Ulrich Schopfer, Ph.D., Novartis Institutes for BioMedical
Laboratory Automation
Research Section (LAS) Executive
Council
Daniel Sipes, Ph.D., Genomics Institute of the Novartis
Research Foundation
Andrew Su, Ph.D., Genomics Institute of the Novartis Malcolm Crook, Ph.D., Process Analysis & Automation, Ltd.
Research Foundation
Jason Abbas, M.S., Syngenta Seeds
Phil Tagari, Ph.D., Amgen
Chris Detter, Ph.D., Los Alamos National Laboratory
Hansjörg Haas, Ph.D., Thermo Fisher Scientific
R. Scott Martin, Ph.D., Saint Louis University
Robyn Rourick, M.S., Genentech
Craig Schulz, Ph.D., Amgen
Nitin Sood, M.S., Agilent Technologies
Kerstin Thurow, Ph.D., Center for Life Science Automation
University of Rostock
Presorted Standard
U.S. Postage
PAID
Permit No. 9711
Chicago, IL
100 Illinois Street, Suite 242

St. Charles, IL 60174 USA
SLAS.org
Thank You to the Sponsors/Media Partners of SBS 2011!

Bronze Sponsors:
Conference Sponsors:
Media Partners:

SLAS SBS OrlandoConference Prelim Program

Caricato da

Informazioni sul documento

Descrizione originale:

Copyright

Formati disponibili

Condividi questo documento

Condividi o incorpora il documento

Opzioni di condivisione

Hai trovato utile questo documento?

Questo contenuto è inappropriato?

Copyright:

Formati disponibili

SLAS SBS OrlandoConference Prelim Program

Caricato da

Copyright:

Formati disponibili

Gaylord Palms Resort and Convention Center

March 27–31, 2011 | Orlando, Florida, USA

What’s New and Exciting for SBS 2011 Page 6

Short Course Program Overview Page 7

Keynote Speakers Page 10

Technical Session Program Overview Page 11

Special Educational Sessions Page 15

SLAS Career Connections Page 15

Special Interest Groups (SIGs) Page 16

General Information Page 19

Social Events and Networking Page 20

Registration Form Page 21

SBS 2011 Scientific Committee, SLAS Board of Directors,

Sponsors and Media Partners Back Cover

• Engaging keynote presentations by SBS Achievement Award winner

• An outstanding scientific program and thought-provoking poster presentations

• Informative vendor tutorials and collaborative Special Interest Groups (SIGs)

• Innovative new programs and awards

As a conference participant, you may choose from 15 diverse scientific sessions

Track I: Innovations in the Screening Sciences

Track II: Translational Research

Track III: Sequenced Genomes: Reducing Opportunities to Practice

Paul Bernasconi and Peter Hodder

9:00 am – 12:00 pm Exhibitor Workshops

5:00 – 6:30 pm Welcome Reception in the Exhibit Hall

12:00 – 4:30 pm Exhibit Hall Open

12:00 – 5:30 pm Exhibit Hall Open

4:30 – 5:30 pm Reception in the Exhibit Hall

12:00 – 1:30 pm Closing Luncheon and Keynote Presentation

Join the SLAS Social Media Communities

SBS 2011 offers:

• Engaging Keynote Presentations

• Enhanced Exhibit Hall Hours and Schedule

• SLAS Smart-Savers Discount Program

• Enhanced SLAS Career Connections

• SLAS New Product Award Designation

Establishing Cell-Based Assays for Screening Label-Free/Biophysics Methods for Screening

Statistical Methods for In Vitro Assays High-Content Screening

Join SLAS and Save Big On SBS 2011

Thought-Provoking Keynote Presentations

Monday, March 28, 9:00 – 11:00 am

Beta Arrestin Mediated Signaling by 7 Transmembrane Receptors: New Therapeutic Opportunities

SBS Accomplishment Award Winner

Thursday, March 31, 12:00 – 1:30 pm

Track I: Innovations in the Screening Sciences

Track II: Translational Research

Track III: Sequenced Genomes: Reducing Opportunities to Practice

Monday, March 28 Schedule subject to change

Track I » Session 1: SLAS Session: Next Generation Technologies:

Track II » Session 4: Development of Novel Anti-Cancer Therapeutics

Sunday, March 27, 1:00 – 4:00 pm

Tuesday, March 29, 1:15 – 2:15 pm Monday – Tuesday, March 28 – 29

Tuesday, March 29, 2:00 – 4:00 pm

Data and Image Analysis Stem Cells in Drug Discovery

NEW Exhibit Hours for 2011!

NEW! New Product Award (NPA) Designations at SBS 2011

Exhibitors (as of December 8)

Gaylord Palms Resort & Convention Center

$239 Single/Double Occupancy Deposit:

Airline Reservations SLAS Creates Smart-Savers Discount

Wednesday, March 30 8:00 am – 5:30 pm Discounted Registration for Groups

Learn more about the Smart-Savers Discount

Name Primary Area of Interest: (check only one)